<DOC>
	<DOCNO>NCT01623895</DOCNO>
	<brief_summary>To investigate effect genetic variation toxicity find optimal target population , investigator plan analyze genetic polymorphism UDP-glucuronosyltransferase .</brief_summary>
	<brief_title>Pharmacogenetic Study Patients Received Iron Chelating Agent</brief_title>
	<detailed_description>Transfusion-associated iron overload induces systemic toxicity . Recently , deferasirox , convenient long act oral agent , introduce clinical practice promise efficacy . However , patient experience drug-related toxicity tolerate . To investigate effect genetic variation toxicity find optimal target population , plan analyze genetic polymorphism UDP-glucuronosyltransferase 1A ( UGT1A ) subfamily , multi-drug resistance-associated protein 2 ( MRP2 ) breast cancer resistance protein ( BCRP ) among pediatric patient receive deferasirox .</detailed_description>
	<mesh_term>Hemosiderosis</mesh_term>
	<mesh_term>Iron Chelating Agents</mesh_term>
	<mesh_term>Chelating Agents</mesh_term>
	<criteria>1 . Patients receive deferasirox transfusion associate iron overload ( Transfusion associate iron overload define ferritin â‰¥ 1,000 ng/mL patient need 8 unit RBC transfusion per year ) . 2 . Patients write informed consent Patients parent refusal</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>